Global Prevalence and Major Risk Factors of Diabetic Retinopathy
By Mbbs J OANNE W.Y. Y AU, Mepid S OPHIE L. R OGERS, Phd R YO K AWASAKI, Phd E COSSE L. L AMOUREUX, Pharmd J ONATHAN W. K OWALSKI, Phd T OKE B EK, Phd S HIH -J EN C HEN, Phd J ACQUELINE M. D EKKER, Phd A STRID F LETCHER, MD J AKOB G RAUSLUND and 26 more. 2012
4,761 citations recorded by the source corpus.
OBJECTIVE To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Subfields: Epidemiology, Ophthalmology, Radiology, Nuclear Medicine and Imaging
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Ophthalmology
In Radiology, Nuclear Medicine and Imaging
- Daniel Shu Wei Ting
- Michael David Abràmoff
- Michael Hirsch
- Tien Yin Wong
- Antonio Ceriello
- Jan M. Köhler
Citations in the corpus
- Artificial intelligence for diabetic retinopathy screening: a review (2019, background): “The prevalence of diabetic retinopathy (DR), a primary cause of blindness and vision loss worldwide, was estimated at 93 million in 2012—out of which 28 million people had vision-threatening DR—and this is also expected to further increase [2, 3].”
- Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications (2019, background): “6%, comparing BP 140/90 or> 140/ 90mmHg).(31) Glycaemic control represents an effective treatment to slow the progression of DR: a meta-analysis of four randomised trials (Action to Control Cardiovascular Risk in Diabetes, Action in Diabetes and Vascular Disease, UKPDS and Veterans Affairs Diabetes ”
- Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes (2017, methodology): “Next, the following subsidiary analyses were performed: (1) the analyses were repeated excluding patients who appeared in both the SIDRP 2010-2013 training set and the primary validation set of SIDRP 2014-2015 (n = 6291 seen more than once in SIDRP), with the patient treated as having referable diab”